In 1997, two major discoveries contributed to the understanding of the pathogenesis of Parkinson's disease (PD). Firstly, the identification of mutations in the alpha-synuclein gene (SNCA) as being responsible for hereditary forms of PD 1 and, secondly, the finding that aggregated, misfolded alphasynuclein (ASN) was one of the major components of Lewy bodies and Lewy neurites 2 , the hallmark lesions of sporadic forms of the disease. Other monogenic forms of the disease (LRRK2, and SNCA duplications and triplications) also have ASN deposits as a distinguishing pathological feature 3 . Other parkinsonian syndromes (multiple system atrophy and dementia with Lewy bodies) were found to be part of a spectrum of disorders, sharing the accumulation of misfolded ASN at the neuronal and glial level, giving birth to the concept of synucleinopathies: neurodegenerative diseases whose pathological marker is the presence of these deposits of abnormally conformed ASN ; pathologic accumulation of ASN is toxic and can interfere with normal synaptic function, dopamine transport, and protein degradation 8 . Moreover, a widespread distribution of ASN pathology, at both the central and peripheral levels, reflects the expression of symptoms of PD, establishing that the disease is a multisystem disorder with both motor and non-motor symptomatology 9 . Another pivotal contribution to our understanding of the pathogenesis of PD has been the comprehensive and detailed description by Braak et al. 10 of the spreading of ASN pathology in the brain of affected individuals. According to their findings, these authors established a pattern of disease progression that correlated with brain ASN pathology in which the course of the disease evolved in stages (I through VI) of increasing involvement. In stages I and II, the areas of 
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In 1997, two major discoveries contributed to the understanding of the pathogenesis of Parkinson's disease (PD). Firstly, the identification of mutations in the alpha-synuclein gene (SNCA) as being responsible for hereditary forms of PD 1 and, secondly, the finding that aggregated, misfolded alphasynuclein (ASN) was one of the major components of Lewy bodies and Lewy neurites 2 , the hallmark lesions of sporadic forms of the disease. Other monogenic forms of the disease (LRRK2, and SNCA duplications and triplications) also have ASN deposits as a distinguishing pathological feature 3 . Other parkinsonian syndromes (multiple system atrophy and dementia with Lewy bodies) were found to be part of a spectrum of disorders, sharing the accumulation of misfolded ASN at the neuronal and glial level, giving birth to the concept of synucleinopathies: neurodegenerative diseases whose pathological marker is the presence of these deposits of abnormally conformed ASN 4 . A significant body of evidence has accumulated in the last 20 years, pointing to a central role of ASN in the pathogenesis of PD. Alpha-synuclein, as mentioned above, is the major component of the pathological hallmark lesions of PD (Lewy bodies and Lewy neurites) 2 ; point mutations in the SNCA cause familial forms of PD 1 ; increased levels of ASN (gene dose effect caused by duplications and triplications of the SNCA) can cause familial forms of PD in which the amount of coded protein correlates with the severity of disease 5 ; specific SNCA variants or polymorphisms confer the risk of developing idiopathic PD 6 ; overexpression of human ASN in experimental animals recapitulates the key features of PD 7 ; pathologic accumulation of ASN is toxic and can interfere with normal synaptic function, dopamine transport, and protein degradation 8 . Moreover, a widespread distribution of ASN pathology, at both the central and peripheral levels, reflects the expression of symptoms of PD, establishing that the disease is a multisystem disorder with both motor and non-motor symptomatology 9 . Another pivotal contribution to our understanding of the pathogenesis of PD has been the comprehensive and detailed description by Braak et al. 10 of the spreading of ASN pathology in the brain of affected individuals. According to their findings, these authors established a pattern of disease progression that correlated with brain ASN pathology in which the course of the disease evolved in stages (I through VI) of increasing involvement. In stages I and II, the areas of 1 the brain initially affected, the olfactory bulb and the dorsal motor nucleus of the vagus nerve (DMNV) correlate with the early presence of autonomic disturbances (constipation) and olfactory loss. Ascending pathology in stages III and IV, involving the locus coeruleus and substantia nigra, correlates with the development of sleep disorders and the initial appearance of motor symptomatology. Further spreading of the pathology to subcortical and cortical structures, characteristic of stages V and VI, heralds the development of cognitive and psychiatric disturbances. Although a significant number of cases fit this staged progression of the disease, according to Braak's hypothesis, some exceptions have been reported. Postmortem studies show that between 6.3% and 43% of cases do not follow the proposed caudo-rostral progression pattern of ASN pathology 11 . In 7% to 8.3% of clinically-manifest PD cases, with ASN inclusions in the midbrain and cortex corresponding to Lewy body stages IV-V, the medullary nuclei were spared, whereas mild parkinsonian symptoms had already been observed in stages II and III 11 . Another controversial issue surrounding this hypothesis revolves around the potential pathogenic role of ASN. Evidence, based on experimental findings, suggests that soluble oligomeric /protofibrillar aggregates are the most neurotoxic forms of ASN 12 . These species, as well as the ready-formed fibrils, may also potentiate pathology by acting as seeds for the formation of additional aggregates 13 . Many intra-and extracellular targets have been singled out as potential sites for toxicity by these forms of ASN. They could interfere with pore formation at the cell membrane level leading to loss of ion homeostasis; cause impairment of protein degradation by the ubiquitin-proteasome system and the autophagy-lysosomal pathway; and compromise cellular respiration through impairment of the mitochondrial machinery 8 . At the peripheral level, it is proposed that pathologic ASN aggregates may cause impairment of synaptic transmission and disturbance of axonal function leading to the demise of the neuron through a process similar to a "dying-back" neuropathy 8 . In support of the synaptotoxic effects of oligomeric forms of ASN, experimental evidence shows that incubation of brain tissue slices with recombinant ASN oligomers impairs long-term potentiation 14 . Another issue subject to debate is related to the spreading of ASN pathology from cell to cell through a "prion-like" mechanism. The first such evidence originated in the postmortem finding of ASN pathology in implanted fetal grafts, after a prolonged incubation period, in the brains of PD patients receiving these implants 13 . This finding prompted a number of experiments trying to support this hypothesis. Injections of pathologic ASN or preformed ASN fibrils into the brains of transgenic and nontransgenic mice were able to initiate a rapidly-progressive PD-like neurodegenerative α-synucleinopathy 15, 16 . Likewise, injection of synthetic ASN fibrils into the brains of non-transgenic primates induced PD-like ASN pathology within only three months after injection 17 . Moreover, Lewy body extracts from PD brains were able to trigger ASN pathology and neurodegeneration in mice and monkeys 18 . Using A30P ASN mice, researchers were able to prove that the degree of pathological involvement and the corresponding development of motor impairment was tightly correlated with the levels of ASN oligomers 19 . In all cases, not only was there evidence of ASN induced pathology, but the pathological process spread throughout the brain.
Additional evidence supporting the hypothesis of ASNinduced toxicity came from experiments using a different approach. In these experiments, the intraperitoneal administration of monoclonal antibodies specific for misfolded ASN into non-transgenic mice, injected intrastriatally with preformed ASN fibrils, was able to reduce Lewy body/Lewy neurite pathology, ameliorate substantia nigra dopaminergic neuron loss, and improve motor impairments 20 . Based on all the evidence presented in the preceding paragraphs, a pathogenic hypothesis has emerged in the last few years. Accumulation of ASN in the DMNV, considered to be the first vulnerable region of the central nervous system to become affected in PD, may actually originate in the enteric nervous system (ENS), where vagal fibers synapse with parasympathetic ganglionic neurons. A putative pathogen capable of passing through the mucosal lining of the gastrointestinal tract might induce ASN misfolding in the terminal axons of postganglionic enteric neurons followed by retrograde transport to the cholinergic preganglionic neurons of the DMNV, and from there spread in a caudo-rostral direction, involving other brain structures, as proposed by Braak et al. Let us review some of the evidence in support of this hypothesis. Epidemiological studies have shown that involvement of the gastrointestinal tract is a very early non-motor symptom of PD. Constipation has been found to predate the appearance of motor symptoms by more than 10 years as documented in several reports 22, 23 . The presence of early ASN immunostaining in the ENS has been found repeatedly in several studies analyzing surgical specimens both in PD-affected individuals and in controls 24 . Post mortem studies in PD patients at different stages of the disease show the presence of ASN immunostaining along the vagal nerve and into the DMNV 25 . Alpha-synuclein is normally secreted by enteric neurons and functional studies show increased intestinal permeability, which correlates with sigmoid mucosa ASN staining and endotoxin exposure markers in early PD 26, 27 . Furthermore, exposure of the ENS to environmental toxins (e.g. rotenone) reproduced ASN pathology and spreading in mice, providing support to the hypothesis of an environmental pathogen acting on the ENS as the initial trigger of ASN pathology 28 . Additional evidence highlighting the importance of the ENS in the pathogenesis of PD comes from the observation that, in mice overexpressing ASN, the gut microbiota are required for motor deficits, microglia activation, and ASN pathology 29 . Administration of antibiotics to these animals was found to improve both the pathology and motor deficits, while microbial recolonization promoted pathophysiological changes 29 . This evidence suggest that postnatal signaling between the gut and the brain is also capable of modulating disease expression.
In support of the hypothesis of the spreading of ASN along the vagal nerve, several experiments have used different approaches 30, 31 (accumulation of human ASN within medullary neurons was achieved via retrograde transport of adeno-associated viral vectors unilaterally injected into the vagus nerve in the rat neck; injection in the intestinal wall of a human PD brain lysate containing different forms of ASN [monomeric, oligomeric and fibrillary], and recombinant ASN in an in vivo animal model was transported via the vagal nerve and reached the DMNV in the brainstem in a time-dependent manner). These different approaches have provided evidence of the possibility of such a mechanism taking place in human disease 30, 31 . Moreover, in more recent studies using rotenone locally applied to the enteric wall to trigger ASN pathology and progression in mice, surgical section of the autonomic nerves was able to stop progression 28 . Two recent epidemiological studies conducted in Sweden and Denmark found a reduced risk of the development of PD in individuals who underwent truncal vagotomy in comparison with those who were treated with selective or super-selective vagotomy for peptic ulcer disease, suggesting that sectioning of the vagus nerve theoretically would have prevented spreading of ASN pathology originated in the ENS 32, 33 ( Figure 2 ). Despite the mounting evidence in favor of this hypothesis, there are still some unanswered questions that cast doubt on its validity. Evidence of preceding constipation in PD patients may have been influenced by recall bias, and correlation in the aged individuals is less strong, while some individuals with positive immunostaining for ASN in the colonic mucosa had no constipation 24 ; Braak's staging system is not applicable in all cases 11 ; the presence of ASN immunostaining in the ENS has been found both in affected individuals and control cases alike 24 ; and there is uncertainty as to the pathogenic relevance of enteric ASN immunostaining 24 . These caveats will hopefully fuel the development of more specific immunostaining techniques and prospective longitudinal studies to look, in more detail, at the progression of ASN pathology. 
